CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
Fisetindrug
Likely dose
Fisetin 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05416515
NCT05416515Phase 2Completed
CompareCT.gov

Phase 2 Clinical Trial of FIsetin to Treat CArpal Tunnel Syndrome (FITCATS)

Peter C. Amadio, M.D.·interventional·Posted Jun 13, 2022·Updated Dec 24, 2025

In Brief

A Phase 2 clinical trial evaluating Fisetin for Carpal Tunnel Syndrome. Completed, enrolled 40 participants across 1 site.

Detailed Summary

This research study is being conducted to investigate the safety and effectiveness of the drug Fisetin for mild or moderate carpal tunnel syndrome (CTS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarpal Tunnel Syndrome
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2023202420252026
First PostedJun 13, 2022
Enrollment StartOct 9, 2022
Primary CompletionDec 31, 2024
Study CompletionJan 24, 2025
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.1 years ago

Interventions

Fisetindrug

100 mg capsules orally for 2 consecutive days and, after 1 month, another 2 consecutive days